2024
USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years
Siddique S, Wang R, Yasin F, Gaddy J, Zhang L, Gross C, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Network Open 2024, 7: e2436358. PMID: 39361285, PMCID: PMC11450516, DOI: 10.1001/jamanetworkopen.2024.36358.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceUS Preventive Services Task Force recommendationsColorectal cancer screening uptakeAverage-risk individualsScreening uptakeHigher socioeconomic statusSocioeconomic statusScreening recommendationsColorectal cancerColorectal cancer screening recommendationsPreventive Services Task ForceCohort studyCancer screening recommendationsScreening uptake ratesInterrupted time series analysisLow socioeconomic statusPrivate insurance beneficiariesScreening ratesSocioeconomic disparitiesRetrospective cohort studyMain OutcomesPotential disparitiesEvaluate changesClaims dataAbsolute change
2022
The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis
Goksu SY, Ozer M, Goksu BB, Wang R, Khatib J, Patel PA, Vusirikala M, Cole S, Seyhanli A, Collins RH, Chung S, Zeidan AM, Madanat YF. The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leukemia & Lymphoma 2022, 63: 1651-1659. PMID: 35133215, DOI: 10.1080/10428194.2022.2032034.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosNon-Hispanic whitesMyelodysplastic syndromeRace/ethnicityNHB patientsNon-Hispanic blacksSurvival outcomesDisease characteristicsAge groupsHigher incidence rate ratioLower incidence rate ratiosOutcomes of patientsBetter overall survivalPopulation-based analysisAcute myeloid leukemiaNHW patientsAdult patientsOverall survivalSEER databaseClinical outcomesIncidence rateMyeloid leukemiaPatientsEthnic backgroundDisease riskPractice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
Bewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.Peer-Reviewed Original ResearchConceptsAcute promyelocytic leukemiaAdverse outcomesPromyelocytic leukemiaNational Comprehensive Cancer Network guidelinesBaseline white blood cell countFavorable long-term prognosisWhite blood cell countVizient Clinical Data BaseGuideline-concordant regimensGuideline-concordant therapyGuideline-concordant treatmentGuideline-recommended therapiesBaseline clinical characteristicsHigh-risk diseaseLong-term prognosisPopulation-based registryBlood cell countClinical data baseLarge database analysisLogistic regression modelsTreatment concordanceClinical characteristicsReal-world practiceTreatment patternsNetwork guidelinesChanges in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2021
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptakeRegional Adoption of Commercial Gene Expression Testing for Prostate Cancer
Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncology 2021, 7: 52-58. PMID: 33237277, PMCID: PMC7689565, DOI: 10.1001/jamaoncol.2020.6086.Peer-Reviewed Original ResearchConceptsProstate cancerCohort studyGenomic testingTissue-based genomic testsProportion of patientsDynamic cohort studyProstate cancer careProstate cancer screeningHospital referral region levelCommercial health insuranceGene expression testingEligible patientsMedian ageCancer careCancer screeningInclusion criteriaFindings highlight factorsHRR levelMAIN OUTCOMEAdministrative claimsGroup 2Group 1Medicare beneficiariesPatientsMedian household income
2020
Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa RA, Ma X. Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2343-2350. PMID: 32868318, PMCID: PMC8895351, DOI: 10.1158/1055-9965.epi-20-0592.Peer-Reviewed Original ResearchConceptsRisk of MPNPolycythemia veraEssential thrombocythemiaMyeloproliferative neoplasmsHazard ratioSugar intakeDietary factorsMultivariable Cox proportional hazards modelsRisk of PVCox proportional hazards modelHigh sugar intakeNIH-AARP DietIntake of fatConfidence intervalsNIH-AARP cohortRole of dietProportional hazards modelPotential confounding variablesParticipants ages 50Warrants further investigationProspective cohortHigh intakePV riskAge 50Health StudyPatterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.Peer-Reviewed Original ResearchConceptsIntensive induction chemotherapyAcute myeloid leukemiaHospital deathInduction chemotherapyAdult patientsMultivariable logistic regression modelLow hospital volumePremier Healthcare DatabasePredictors of deathHealthcare resource utilizationIntensive care unitPatterns of careStandard of careLogistic regression modelsFit patientsRemission inductionFirst hospitalizationHospital volumeInpatient deathInpatient mortalityOlder patientsSupportive careMedian ageAML patientsCare unitLifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study. International Journal Of Cancer 2020, 147: 948-957. PMID: 31904114, PMCID: PMC8919268, DOI: 10.1002/ijc.32853.Peer-Reviewed Original ResearchConceptsNIH-AARP DietPolycythemia veraMyeloproliferative neoplasmsEssential thrombocythemiaHazard ratioLifestyle factorsCaffeine intakeHealth StudyMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelRisk of PVProportional hazards regression modelsRisk of MPNLarge prospective studiesHazards regression modelsConfidence intervalsPhiladelphia chromosome-negative myeloproliferative neoplasmsMPN riskOverall cohortProspective cohortProspective studyInverse associationRisk factorsPV riskProtective effect
2012
Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults
Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsStandardized incidence ratiosSolid second malignant neoplasmsExtended field radiotherapyRecent treatment optionsLow-dose radiationSMN riskSubsequent malignanciesModality therapyIncidence ratiosHodgkin's lymphomaTreatment optionsMalignant neoplasmsSubgroup analysisCMT groupLower incidenceHigh riskGeneral populationAlkylator chemotherapyPatientsDose radiationRiskRadiotherapyChildrenAdults
2011
Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
Ma X, Wang R, Galili N, Mayne ST, Wang SA, Yu H, Raza A. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. Cancer Causes & Control 2011, 22: 623-629. PMID: 21287258, PMCID: PMC3086405, DOI: 10.1007/s10552-011-9735-6.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesSurvival of patientsRisk of deathMyelodysplastic syndromeMDS survivalLifestyle factorsMultivariate Cox proportional hazards modelHigh-risk myelodysplastic syndromeCox proportional hazards modelLow-risk patientsProportional hazards modelInitial clinical encounterClinical characteristicsHazard ratioIndependent predictorsPrognostic roleMDS patientsCigarette smokingPoor survivalHematological malignanciesElevated riskHazards modelPatientsSmokingClinical encounters
2009
Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH–AARP Cohort
Ma X, Park Y, Mayne ST, Wang R, Sinha R, Hollenbeck AR, Schatzkin A, Cross AJ. Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH–AARP Cohort. American Journal Of Epidemiology 2009, 171: 312-322. PMID: 20042434, PMCID: PMC2842202, DOI: 10.1093/aje/kwp371.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaPack/dayMyeloid leukemiaHazard ratioMeat intakeNIH-AARP DietLarge prospective studiesMultivariate Cox modelHigh meat intakeMeat cooking methodsNIH-AARP cohortCurrent smokersFormer smokersIncident casesProspective studyUS cohortVegetable intakeDoneness levelRisk factorsHigh riskCox modelHealth StudyLeukemiaSmokersConfidence intervalsA Birth Cohort Analysis of the Incidence of Papillary Thyroid Cancer in the United States, 1973–2004
Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, Bai Y, Wang R, Zhu Y, Zhang Y. A Birth Cohort Analysis of the Incidence of Papillary Thyroid Cancer in the United States, 1973–2004. Thyroid 2009, 19: 1061-1066. PMID: 19732011, PMCID: PMC2833179, DOI: 10.1089/thy.2008.0342.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerBirth-cohort patternThyroid cancerIncidence trendsCohort patternsNational Cancer Institute's SurveillanceCohort modelingEnd Results ProgramBirth cohort effectsObserved incidence trendsBirth cohort analysisPapillary thyroid carcinomaSmall thyroid nodulesCohort-related changesObserved time trendsPeriod effectsResults ProgramCohort analysisThyroid carcinomaBirth cohortIncidence patternsThyroid nodulesCancerIncidenceStudy periodObesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort
Ma X, Lim U, Park Y, Mayne ST, Wang R, Hartge P, Hollenbeck AR, Schatzkin A. Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort. American Journal Of Epidemiology 2009, 169: 1492-1499. PMID: 19395696, PMCID: PMC2727203, DOI: 10.1093/aje/kwp074.Peer-Reviewed Original ResearchConceptsRisk of MDSMyelodysplastic syndromeLifestyle factorsPhysical activityUS prospective studiesHealth-AARP DietLarge US cohortModifiable risk factorsBody mass indexRelation of obesityCurrent smokersFormer smokersMass indexSignificant positive associationAlcohol intakeCigarette smokingProspective studyProspective InvestigationUS cohortVegetable intakeRisk factorsMeat intakeHealth StudyAlcohol consumptionSmokers
2008
Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma in Connecticut Women
Wang R, Zhang Y, Lan Q, Holford TR, Leaderer B, Zahm SH, Boyle P, Dosemeci M, Rothman N, Zhu Y, Qin Q, Zheng T. Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma in Connecticut Women. American Journal Of Epidemiology 2008, 169: 176-185. PMID: 19056833, PMCID: PMC2727253, DOI: 10.1093/aje/kwn300.Peer-Reviewed Original ResearchConceptsRisk of NHLNon-Hodgkin lymphomaOccupational exposureConnecticut womenPopulation-based case-control studyOverall non-Hodgkin lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaCase-control studyB-cell lymphomaJob-exposure matrixIncident casesNHL subtypesBenzene exposureLymphomaRisk patternsWomenRiskExposureCarbon tetrachlorideAssociationBorderlineWork settingsLevelsStrong evidence
2007
Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma
Zhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R, Zou K, Zhang B, Wise JP, Qin Q, Kilfoy B, Han J, Zheng T. Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma. American Journal Of Epidemiology 2007, 165: 1255-1264. PMID: 17327216, DOI: 10.1093/aje/kwm020.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaLymphoma subtypesNon-Hodgkin lymphomaCase-control studyHodgkin lymphoma subtypesUltraviolet radiation exposureHighest tertileConnecticut womenSun exposureLymphomaRadiation exposureDuration of timeWomenSuntanRiskFurther investigationDurationExposureTertileYearsSubtypesMonths